Regeneron price target lowered to $769 from $778 at Truist
Truist lowered the firm's price target on Regeneron to $769 from $778 and keeps a Buy rating on the shares as part of a broader research note previewing Q2 earnings in Biotech. The firm is anticipating a rebound from a traditionally softer start to the year, with strength in Q2 prints for commercial franchises within i